PROCEPT BioRobotics trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth. Learn why PRCT stock is a buy.
1mon
PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported ...
Full-year 2025 revenue guidance was updated to approximately $323 million, reflecting 44% growth compared to 2024. This includes US system revenue of $95 million, driven by greenfield sales and some ...
PROCEPT BioRobotics Corp. (NASDAQ:PRCT) is one of the best pure-play robotics stocks to buy now. PROCEPT BioRobotics Corp. (NASDAQ:PRCT) is among the best pure-play robotics stocks to buy now. The ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. PROCEPT BioRobotics (PRCT) is back in focus after its Q4 2025 revenue miss, softer ...
PROCEPT BioRobotics' Aquablation therapy has been upgraded to a strong recommendation in the updated European Association of Urology Guidelines as a preferred surgical treatment for benign prostatic ...
Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasiaSAN JOSE, Calif., March 23, ...
In its fourth quarter of 2025, PROCEPT BioRobotics reported total revenue of $76.4 million, marking a 12% increase compared to the prior year, missing the consensus of $94.14 million. The increase was ...
We recently compiled a list of the 20 Hidden Gem AI Stocks. In this article, we are going to take a look at where PROCEPT BioRobotics Corporation (NASDAQ:PRCT) stands against the other hidden gem AI ...
The company continues to grow revenue. It lost $28.5 million in the first quarter. Procept's lead product is a robotic surgery system used to perform prostate procedures. Procept makes the AquaBeam ...
On Thursday, Spruce Point Capital released a detailed report on PROCEPT BioRobotics (NASDAQ:PRCT), raising concerns about the claims surrounding its market potential and growth prospects, suggesting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results